NCT00383760: Eribulin Mesylate as Second-Line Therapy for Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer Patients |
|
|
| Completed | 2 | 15 | Canada | eribulin mesylate, B1939, E7389, ER-086526, halichrondrin B analog | National Cancer Institute (NCI) | Adenocarcinoma of the Pancreas, Pancreatic Cancer, Recurrent Pancreatic Cancer, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer | 07/11 | 07/11 | | |
